Technology, Electronics Industry
Supplementary content: The third-generation EGFR inhibitor C-005 has recently been approved for clinical trials, becoming one of the very few domestic third-generation anti-viral drugs approved to enter clinical trials. Targeted drug candidates for small cell lung cancer. Shuangliang Biological C-005 plans to officially enter Phase I clinical trials in September this year.
Relying on the company’s core competitiveness and rich drug research and development experience in structure-based innovative drug molecules, Shuangliang Bioscientists’ team has independently developed C-005 in response to the shortcomings of the current third-generation EGFR targeted drugs. It has the characteristics of good curative effect, low toxicity and effective penetration of the blood-brain barrier. From a cost perspective, it is superior to similar foreign products and has a competitive advantage. In addition, focusing on the huge global market, Shuangliang Biotechnology has also implemented global patent protection for C-005. C-005 has obtained the PCT international patent and has obtained patents in Australia, the United States and other countries and regions.